PATIENTS' PRETREAMENT
Ewing sarcoma-patient #1 (ES #1) was diagnosed with multifocal disease and bone marrow (BM) involvement. He received chemotherapy according to Euro-Ewing 2008, proton-beam irradiation of the primary sites, tandem high-dose chemotherapy (HDC) with autologous stem cell rescue (ASCR) followed by haploidentical allogeneic stem cell transplantation (allo-SCT) in complete remission (CR). He developed acute °I-II skin graft-versus-host-disease (GvHD) for 61 days which was controlled by i.v. methylprednisolone. The patient had mixed chimerism for 13 months after allo-SCT until he suffered from a multifocal relapse, which was treated with irinotecan/temozolomide/temsirolimus and six repetitive infusions of donor lymphocytes (DLI) with up to 1 × 10 6 CD3 + cells/kg body weight. ES #2 received Euro-Ewing 99 protocol treatment after being diagnosed with ES metastatic to multiple bones, lungs, and BM. Due to his high-risk profile, the patient received irradiation of all tumor lesions, tandem HDC with ASCR and haploidentical allo-SCT in CR. He suffered from °I skin GvHD and therefore received immunosuppressive drugs for 120 days. After 16 months in CR, a 1st (pulmonary) relapse was treated with salvage chemotherapy and seven doses of DLI with up to 1 × 10 7
CD3
+ cells/kg in combination with hyperthermia and chemotherapy.
ES #3 was diagnosed with multifocal ES and showed disseminated BM involvement. She was treated according to Euro-Ewing 2008 protocol including chemotherapy, irradiation, consecutive tandem HDC and ASCR, followed by HLA-matched allo-SCT. Due to residual disease at the time of allo-SCT, she received two doses of DLI up to 1 × 10 6 CD3 + cells /kg. ES-patient #4 (ES #4) was diagnosed with localized ES and received treatment according to the Euro-Ewing 99 protocol including irradiation and HDC with ASCR. After suffering from a 1st late multifocal relapse, she received irinotecan/temozolomide based rescue therapy followed by irradiation and haploidentical allo-SCT. Due to residual disease at time of allo-SCT, DLI treatment was started with four doses of up to 3 × 10 5 CD3 + cells/kg. RMS-patient #4 (RMS #4) was diagnosed with stage IV alveolar RMS and received treatment according to CWS-IV 2002 protocol, combined with radiotherapy, tandem HDC with ASCR followed by haploidentical allo-SCT in CR. She then suffered from °IV acute GvHD (intestine, skin) after allo-SCT which could be controlled by steroids, MMF, etanercept and third-party mesenchymal stem cells (MSC). In total immunosuppressive MMF was given for 10 months. Distant localized relapse occurred 18 months post-transplantation and was treated with one DLI of 1 × 10 6 CD3 + /kg in combination with hyperthermia and concurrent ifosfamide/carboplatin/etoposide chemotherapy in reduced dosage (mini-ICE).
